NDA 020599 · Azurity
Rilutek
Riluzole · Oral
NovelPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Dec 12, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
97
20 Phase 3, 11 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 1995 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- RILUTEK · RILUZOLE 50MG · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Riluzole" as an intervention, any sponsor and status, largest first.
- Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)Pivotal-lookingTerminated
King's College LondonAcademic, hospital or other
NCT00211224 · 800 participants · Start Apr 2000
Drug: Riluzole · For: Multiple System Atrophy; Progressive Supranuclear Palsy
Sites: London, United Kingdom
- Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingCompleted
CytokineticsIndustry
NCT01709149 · 711 participants · Start Oct 2012 · Primary completion Mar 2014
Drug: CK-2017357; Riluzole · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; La Jolla, California; Orange, California · 75 sites in all
- Riluzole in Huntington's DiseasePivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00277602 · 537 participants · Start Nov 1999 · Primary completion Jul 2004
Drug: Riluzole · For: Huntington Disease
- Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALSPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00868166 · 512 participants · Start Apr 30, 2009 · Primary completion Sep 30, 2011
Drug: Olesoxime; Placebo Comparator and 1 more · For: Amyotrophic Lateral Sclerosis
Sites: Leuven, Belgium; Bron, France; Lille, France · 15 sites in all
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsPivotal-lookingRecruiting
AB ScienceIndustry
NCT03127267 · 495 participants (planned) · Start Feb 2, 2021 · Primary completion Dec 2027
Drug: Masitinib (6.0); Riluzole and 2 more · For: Amyotrophic Lateral Sclerosis
Sites: Birmingham, Alabama; Los Angeles, California; Lexington, Kentucky · 56 sites in all
- MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT01910259 · 445 participants · Start Dec 18, 2014 · Primary completion Jun 14, 2018
Drug: Amiloride; Riluzole and 2 more · For: Secondary Progressive Multiple Sclerosis
Sites: Edinburgh, United Kingdom; Glasgow, United Kingdom; Haywards Heath, United Kingdom · 13 sites in all
- Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT00403104 · 420 participants · Start Nov 2006 · Primary completion Dec 2008
Drug: ONO-2506PO; ONO-2506PO · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Vienna, Austria; Brussels, Belgium; Leuven, Belgium · 26 sites in all
SanofiSanofi (SNY)
NCT00542412 · 414 participants · Start Jan 2001
Drug: Riluzole · For: Amyotrophic Lateral Sclerosis
Sites: Laval, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
Siefried KJ, Acheson LS, Lintzeris N, et al. · CNS Drugs 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG, Mitchell JD, Moore DH · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.
Fehlings MG, Moghaddamjou A, Harrop JS, et al. · J Neurotrauma 2023 · Randomized Controlled Trial, Multicenter Study
- A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
Bensimon G, Lacomblez L, Meininger V · N Engl J Med 1994 · Clinical Trial, Randomized Controlled Trial
- Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Zesiewicz TA, Wilmot G, Kuo SH, et al. · Neurology 2018 · Practice Guideline, Research Support, Non-U.S. Gov't
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL, Hurducas C, Hawton K, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.